I would not look at carryover losses as an asset in a sale or merger. All you have to do is look at the acquisition of Dendreon (DNDN) for some insight.
June 2014 Dendreon's balance sheet is a mess. Per the first quarter, the company reported a net loss of $36.4 million, or $0.24 per share. While Dendreon's cost-cutting measures have helped to shrink this net loss by a substantial 50% year over year, you should keep in mind that the company now has an accumulated deficit of $2.3 billion.
Feb 2015
A bankruptcy judge Friday approved the sale of the assets of Dendreon Corp. , a troubled cancer drug maker, to Valeant Pharmaceuticals International Inc. VRX +0.19% for $495 million.
Everyone in that stock thought they would at least get the value of the tax deficit. DNDN was trading at a low level prior to the announcement of the acquisition. However, the SP did not move up after the acquisition was completed. People lost a lot of money believing the tax writes were going to save their investments.
Accumulated deficit equaled $2.3B
Acquisition total 495M
Good luck with AMDA. The stock trades at this low price for a reason...that is all the company is worth.